Biocept, Inc. (BIOC): Price and Financial Metrics

Biocept, Inc. (BIOC): $0.43

0.07 (-13.05%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

BIOC Price/Volume Stats

Current price $0.43 52-week high $27.00
Prev. close $0.50 52-week low $0.32
Day low $0.40 Volume 751,400
Day high $0.49 Avg. volume 764,067
50-day MA $1.06 Dividend yield N/A
200-day MA $6.35 Market Cap 1.14M

BIOC Stock Price Chart Interactive Chart >



BIOC Latest News Stream


Event/Time News Detail
Loading, please wait...

BIOC Latest Social Stream


Loading social stream, please wait...

View Full BIOC Social Stream

Latest BIOC News From Around the Web

Below are the latest news stories about BIOCEPT INC that investors may wish to consider to help them evaluate BIOC as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start off the workweek with a detailed breakdown of the biggest pre-market stock movers for Monday morning!

William White on InvestorPlace | October 23, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are a hot topic worth checking out on Wednesday and we have all the latest news happening this morning!

William White on InvestorPlace | October 18, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Pre-market stock movers are a hot topic among traders on Thursday and we're offering all of the latest coverage this morning!

William White on InvestorPlace | October 12, 2023

Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases

SAN DIEGO, September 21, 2023--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal metastases (LM) in the feasibility phase of its prospective FORESEE clinical trial (NCT0414123). This trial is evaluating the performance of Biocept’s proprietary CNSide assay in monitoring the response to therapy of LM, a

Yahoo | September 21, 2023

Why Is Cancer Diagnostic Focused Biocept Stock Trading Higher Today?

Biocept Inc (NASDAQ: BIOC) shares are trading higher after the company signed a non-exclusive licensing agreement for CNSide with Plus Therapeutics Inc (NASDAQ: PSTV), which expands the comprehensive laboratory services agreement between the two companies that was announced in June 2022. Benzinga exclusively broke the story. Plus Therapeutics is using CNSide in a clinical trial with their targeted radiotherapeutic to treat patients with carcinomas and/or melanomas with suspected leptomeningeal m

Yahoo | September 8, 2023

Read More 'BIOC' Stories Here

BIOC Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year -80.09%
3-year -99.69%
5-year -99.90%
YTD N/A
2023 0.00%
2022 -85.36%
2021 -18.47%
2020 55.24%
2019 -66.74%

Continue Researching BIOC

Want to see what other sources are saying about Biocept Inc's financials and stock price? Try the links below:

Biocept Inc (BIOC) Stock Price | Nasdaq
Biocept Inc (BIOC) Stock Quote, History and News - Yahoo Finance
Biocept Inc (BIOC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!